Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $5.08 Consensus Price Target from Analysts

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) has received a consensus rating of "Hold" from the four ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $5.08.

Several equities research analysts have recently weighed in on the stock. StockNews.com downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday, August 13th. Chardan Capital restated a "buy" rating and set a $1.25 price objective on shares of Seres Therapeutics in a research note on Wednesday, August 14th. JPMorgan Chase & Co. lowered Seres Therapeutics from a "neutral" rating to an "underweight" rating in a research report on Thursday. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $10.00 price target on shares of Seres Therapeutics in a report on Friday, September 13th.

Insider Transactions at Seres Therapeutics

In related news, insider Teresa L. Young sold 24,480 shares of the business's stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $1.08, for a total transaction of $26,438.40. Following the completion of the transaction, the insider now owns 78,178 shares in the company, valued at $84,432.24. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last ninety days, insiders have sold 28,844 shares of company stock worth $30,104. 5.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MCRB. Vanguard Group Inc. raised its holdings in shares of Seres Therapeutics by 12.1% during the first quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company's stock valued at $5,213,000 after buying an additional 729,514 shares during the last quarter. Vontobel Holding Ltd. acquired a new stake in Seres Therapeutics in the 3rd quarter valued at approximately $374,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Seres Therapeutics during the 2nd quarter valued at $92,000. Virtu Financial LLC acquired a new position in Seres Therapeutics during the 1st quarter worth $73,000. Finally, Point72 DIFC Ltd acquired a new position in Seres Therapeutics during the 2nd quarter worth $64,000. Institutional investors own 59.34% of the company's stock.

Seres Therapeutics Price Performance

MCRB traded down $0.05 on Thursday, reaching $0.71. The company's stock had a trading volume of 2,962,475 shares, compared to its average volume of 4,461,983. Seres Therapeutics has a 1 year low of $0.54 and a 1 year high of $2.05. The business's 50 day moving average is $0.90 and its 200 day moving average is $0.91. The stock has a market cap of $107.54 million, a price-to-earnings ratio of -1.24 and a beta of 2.03.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.08. During the same quarter last year, the company posted $0.36 EPS. As a group, research analysts forecast that Seres Therapeutics will post -0.95 earnings per share for the current fiscal year.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.